Antibodies specific to the attachment protein of Mycoplasma pneumoniae were demonstrated in sera and respiratory secretions of human patients. The results indicate that the attachment protein is a major immunogen.
Mycoplasma pneumoniae is one of the most common causes of human respiratory tract infections (6) and is the principal etiological agent of atypical pneumonia. It has been recognized for some time that M. pneumoniae, as well as other mycoplasma species, can attach firmly to various types of epithelium cells (16) . Previous studies have indicated that attachment of M. pneumoniae to host respiratory epithelium is mediated through a specialized structure at one end of this filamentous organism (4, 5) . Subsequently, we have demonstrated that a surface protein component, designated as P1 protein, is involved in this attachment process (10) . Recently, we have provided direct evidence that P1 protein is localized at the surface of the terminal organelle of M. pneumoniae by using monoclonal antibodies specific for Pl protein (9) . This observation was subsequently confirmed by Feldner et al. (7) and Baseman et al. (1) , who used monoclonal antibody and monospecific antibody, respectively, against P1 protein. Baseman et al. claimed that the Pl protein, although mainly concentrated over the terminal structure, might also be scattered over other parts of the surface of M. pneumoniae. Despite this minor discrepancy, the importance of P1 in the pathogenesis of M. pneumoniae infection is now considered established.
The role of the humoral immune response in protection against M. pneumoniae infection has been well documented (13, 17) , and surface proteins of M. pneumoniae, including P1 protein, have been suggested as possible vaccine candidates (8) . To investigate this possibility, we conducted experiments to study the immunogenicity of the constituent proteins of M. pneumoniae. When Western blot transfer was combined with a radioimmunobinding assay (11) , antibodies to seven immunogens, including P1 protein, were found in the sera of hamsters infected with M. pneumoniae by inhalation. We found that many more proteins were capable of stimulating antibodies in rabbits immunized parenterally with mycoplasmas. The present study extends this technique to human sera and respiratory secretions to ensure that P1 and other M. pneumoniae proteins are also immunogenic for humans.
M. pneumoniae M129 (ATCC 29342), was used in this study. Cultures were maintained in Hayflick medium supplemented with 20% agammaglobulin horse serum, 10% yeast dialysate, and penicillin (1,000 U/ml) (10). Monolayer cultures were grown in glass prescription bottles. After incubation at 37°C for 36 to 48 h, the medium was decanted, and the organisms were rinsed three times with phosphate-buffered saline (pH 7.2). The organisms were then scraped into the phosphate-buffered saline, pelleted by centrifugation (12,000 x g for 15 min), and processed for sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Electrophoresis of M. pneumoniae proteins on sodium dodecyl sulfate-polyacrylamide (10%) and Western blot transfer were the same as described previously (9) . After transfer, the nitrocellulose blots were incubated with sera or respiratory secretions from human patients with culture-proven M. pneumoniae infection and then imaged with "251-labeled goat anti-human immunoglobulin G (IgG), IgM, or secretory IgA (Cappel Laboratories, Cochranville, Pa.). Radioautographs were produced with Xomat-AR5 film (Kodak) at -80°C for 12 to 24 h with an intensifying screen (DuPont Co., Wilmington, Del.).
A total of 12 paired (acute and convalescent) serum samples were examined. Representative data are presented in Fig. 1 . Despite marked variations in each individual's ability to recognize and respond to different mycoplasma antigens, all patients with high complement fixation or radioimmunoassay titers (Table 1) protein as an immunogen in the respiratory tract, respiratory secretions were examined for the presence of antibodies specific to Pl protein.
As shown in Fig. 2 , both IgG and secretory IgA specific for P1 protein could be observed in either sputum or nasal washes from all subjects examined. It is possible that antibodies specific to Pl protein may play a role(s) other than that of antiattachment in the respiratory tract (7). Powell and Clyde (16) reported that phagocytosis of M. pneumoniae by alveolar macrophages can be greatly enhanced by specific antibodies. In addition, monoclonal antibodies specific to Pl protein have been shown to inhibit the hemabsorption activity and motility of M. pneumoniae (7) .
In conclusion, the present studies have demonstrated that patients with natural infection uniformly react to the attachment protein of M. pneumoniae by producing antibodies against it in their blood and respiratory secretions. Identification of this surface protein, which stimulates immunity, suggests the possibility of its use as a vaccine to prevent M. pneumoniae disease.
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